UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended April 2, 2006
OR
TRANSITION REPORT
PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition
period from________to_______
COMMISSION FILE
NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235
East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip
code)
(212) 573-2323
(Registrant's telephone number)
Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days.
YES X NO
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, or a non-accelerated filer. See
definition of "accelerated filer and large accelerated filer" in
Rule 12b-2 of the Exchange Act (Check one):
Large accelerated filer X
Accelerated Filer Non-accelerated
filer
Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act).
YES NO X
At May 2, 2006, 7,327,389,419 shares of the
issuer's voting common stock were outstanding.
FORM 10-Q
For the Quarter
Ended
April 2, 2006
Table
of Contents
PART I. FINANCIAL
INFORMATION
Page
Item 1.
Financial Statements:
Condensed
Consolidated Statements of Income for the three months ended April 2,
2006 and April 3, 2005
Condensed
Consolidated Balance Sheets at April 2, 2006 and
December 31, 2005
Condensed
Consolidated Statements of Cash Flows for the three months ended
April 2, 2006 and April 3, 2005
Notes to
Condensed Consolidated Financial Statements
Review Report
of Independent Registered Public Accounting Firm
20
Item 2.
Management's
Discussion and Analysis of Financial Condition and Results of Operations
21
Item 3.
Quantitative
and Qualitative Disclosures About Market Risk
46
Item 4.
Controls and
Procedures
46
PART II. OTHER
INFORMATION
Item 1.
Legal Proceedings
47
Item 1A.
Risk Factors
48
Item 2.
Unregistered
Sales of Equity Securities and Use of Proceeds
48
Item 3.
Defaults Upon
Senior Securities
48
Item 4.
Submission of
Matters to a Vote of Security Holders
48
Item 5
Other
Information
50
Item 6.
Exhibits
50
Signature
51
PART
I - FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
(millions
of dollars, except per common share data)
April 2,
2006
April 3,
2005
Revenues
12,660
13,091
Costs
and expenses:
Cost of sales(a)
1,973
2,191
Selling, informational and administrative expenses(a)
3,810
4,085
Research and development expenses(a)
1,588
1,764
Amortization of intangible assets
828
882
Merger-related in-process research and development
charges
--
Restructuring charges and merger-related costs
306
219
Other (income)/deductions - net
(272)
1,038
Income from continuing operations before provision
for taxes on income and minority interests
4,427
2,910
Provision for taxes on income
315
2,635
Minority interests
Income from continuing operations
4,108
272
Discontinued operations:
Loss from discontinued operations - net of tax
--
(12)
Gains on sales of discontinued operations - net of
tax
41
Discontinued operations - net of tax
29
Net income
4,111
301
Earnings
per common share - basic:
Income from continuing operations
0.56
0.04
Discontinued operations - net of tax
--
--
Net income
0.56
0.04
Earnings
per common share - diluted:
Income from continuing operations
0.56
0.04
Discontinued operations - net of tax
--
--
Net income
0.56
0.04
Weighted-average shares used to calculate earnings
per common share:
Basic
7,314
7,416
Diluted
7,324
7,474
Cash
dividends paid per common share
0.24
0.19
(a)
Exclusive
of amortization of intangible assets, except as disclosed in Note 11B, Goodwill
and Other Intangible Assets: Other Intangible Assets.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(millions
of dollars)
April 2,
2006*
Dec. 31,
2005**
ASSETS
Current Assets
Cash and cash
equivalents
2,869
2,247
Short-term
investments
12,633
19,979
Accounts
receivable, less allowance for doubtful accounts
10,352
9,765
Short-term
loans
445
510
Inventories
6,663
6,039
Prepaid
expenses and taxes
4,302
3,196
Assets held for
sale
151
160
Total current assets
37,415
41,896
Long-term
investments and loans
2,543
2,497
Property, plant and equipment, less
accumulated depreciation
17,103
17,090
Goodwill
23,741
23,774
Identifiable
intangible assets, less accumulated amortization
28,073
27,786
Other assets,
deferred taxes and deferred charges
4,084
4,522
Total assets
112,959
117,565
LIABILITIES
AND SHAREHOLDERS' EQUITY
Current Liabilities
Short-term
borrowings, including current portion of long-term debt
5,059
11,589
Accounts
payable
1,892
2,226
Dividends
payable
1,772
Income taxes
payable
3,495
3,617
Accrued
compensation and related items
1,504
1,675
Other current
liabilities
7,717
7,522
Liabilities held
for sale
Total current liabilities
19,674
28,403
Long-term debt
6,508
6,347
Pension benefit
obligations
2,665
2,717
Postretirement
benefit obligations
1,448
1,443
Deferred taxes
10,337
10,240
Other
noncurrent liabilities
2,718
2,651
Total liabilities
43,350
51,801
Shareholders' Equity
Preferred stock
159
169
Common stock
439
439
Additional
paid-in capital
67,931
67,759
Employee
benefit trust, at fair value
(729)
(923)
Treasury stock
(40,757)
(39,767)
Retained
earnings
41,715
37,608
Accumulated
other comprehensive income
851
479
Total shareholders' equity
69,609
65,764
Total liabilities and shareholders'
equity
112,959
117,565
* Unaudited.
** Condensed from audited
financial statements.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Three Months Ended
(millions
of dollars)
April 2,
2006
April 3,
2005
Operating Activities:
Net income
4,111
301
Adjustments to reconcile net income to net cash
provided by continuing operating activities:
Depreciation and amortization
1,351
1,366
Share-based compensation expense
172
22
Merger-related in-process research and development
charges
--
Intangible asset impairments and other associated
non-cash charges
--
1,213
Gains on disposal of investments, products and
product lines
(76)
(4)
Loss from discontinued operations
--
18
Gains on sales of discontinued operations
(5)
(65)
Deferred taxes from continuing operations
(714)
483
Other deferred taxes
--
(4)
Other non-cash adjustments
25
98
Changes in assets and liabilities (net of businesses
acquired and divested)
(903)
(237)
Net
cash provided by continuing operating activities
3,961
3,193
Investing
Activities:
Purchases of property, plant and equipment
(418)
(465)
Purchases of short-term investments
(2,735)
(4,891)
Proceeds from redemptions of short-term investments
10,438
2,531
Purchases of long-term investments
(216)
(494)
Proceeds from sales of long-term investments
437
Purchases of other assets
(35)
(70)
Proceeds from sales of other assets
Proceeds from the sales of businesses, product lines
and other products
93
Acquisitions, net of cash acquired
(1,440)
--
Other investing activities
(177)
149
Net
cash provided by/(used in) investing activities
5,431
(2,705)
Financing
Activities:
Increase in short-term borrowings, net
826
1,591
Principal payments on short-term borrowings
(8,056)
(205)
Proceeds from issuances of long-term debt
1,035
Principal payments on long-term debt
(1)
(1)
Purchases of common stock
(1,000)
(919)
Cash dividends paid
(1,743)
(1,400)
Stock option transactions and other
173
115
Net cash used in financing activities
(8,766)
(818)
Effect of exchange-rate changes on cash and cash
equivalents
(4)
(2)
Net increase/(decrease) in cash and cash equivalents
622
(332)
Cash and cash equivalents at beginning of period
2,247
1,808
Cash and cash equivalents at end of period
2,869
1,476
Supplemental Cash Flow Information:
Cash paid during the period for:
Income taxes
640
557
Interest
213
141
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER
INC AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation
We prepared the condensed consolidated financial statements
following the requirements of the Securities and Exchange Commission (SEC) for
interim reporting. As permitted under those rules, certain footnotes or other
financial information that are normally required by accounting principles
generally accepted in the United States of America (GAAP) can be condensed or
omitted. Balance sheet amounts and operating results for subsidiaries operating
outside the U.S. are as of and for the three-month periods ended
February 26, 2006 and February 27, 2005.
We made certain reclassifications to the 2005 condensed
consolidated financial statements to conform to the 2006 presentation.
Revenues, expenses, assets and liabilities can vary during
each quarter of the year. Therefore, the results and trends in these interim
financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements
included in this document. The financial statements include all normal and
recurring adjustments that are considered necessary for the fair presentation
of our financial position and operating results.
The information included in this Quarterly Report on
Form 10-Q should be read in conjunction with the consolidated financial
statements and accompanying notes included in Pfizer's Annual Report on
Form 10-K for the year ended December 31, 2005.
Note 2. Acquisitions and Dispositions
A. Acquisitions
On February 28, 2006, we completed the acquisition of the sanofi-aventis
world-wide rights, including patent rights and production technology, to
manufacture and sell Exubera, an inhaled form of insulin for use in adults with
type 1 and type 2 diabetes, and the insulin-production business and facilities
located in Frankfurt, Germany, previously jointly owned by Pfizer and sanofi-aventis,
for approximately $1.4 billion (including transaction costs). In
connection with the acquisition, as part of our preliminary purchase price
allocation, we recorded an intangible asset for developed technology rights of
approximately $1.0 billion, inventory valued at $218 million and
goodwill of approximately $166 million, all of which have been allocated
to our Human Health segment. The amortization of the developed technology
rights will be primarily included in Cost of Sales. Given the size and
complexity of the acquisition, the fair valuation and allocation work is still
being finalized and is expected to be substantially complete in the second
quarter. To the extent that our estimates need to be adjusted, we will do so.
Prior to the acquisition, in connection with our
collaboration agreement with sanofi-aventis, we recorded a research and
development milestone due to us from sanofi-aventis of approximately $118 million
($71 million, after tax) in Research and development expenses upon
the approval of Exubera in January 2006 by the Food and Drug Administration
(FDA).
B. Dispositions
We evaluate our businesses and product lines periodically
for strategic fit within our operations. As a result of our evaluation, we
decided to sell a number of businesses and product lines, certain of which
qualified for Discontinued operations treatment. As of December 31, 2005,
all of the transactions were completed. The impact of these divested businesses
and product lines was not material to the consolidated operating results of
Pfizer in the periods presented.
Assets held for sale
and Liabilities held for sale
on the balance sheet at April 2, 2006 and December 31, 2005, relate
primarily to assets in Europe that we intend to sell but that are not related
to Discontinued operations.
Note 3. Adoption of New Accounting Standards
On January 1, 2006, we adopted the provisions of Statement of
Financial Accounting Standards (SFAS) No. 123R, Share-Based Payment, as
supplemented by the interpretation provided by SEC Staff Accounting Bulletin
(SAB) No. 107, issued in March 2005. (SFAS 123R replaced SFAS 123, Stock-Based
Compensation, issued in 1995.) We have elected the modified prospective
application transition method of adoption and, as such, prior period financial
statements have not been restated. Under this method, the fair value of all stock
options granted or modified after adoption must be recognized in the consolidated
statement of income and total compensation cost related to nonvested awards not
yet recognized, determined under the original provisions of SFAS 123, must also
be recognized in the consolidated statement of income.
Prior to January 1, 2006, we accounted for stock options
under Accounting Principle Board Opinion (APB) No. 25, Accounting for Stock
Issued to Employees, an elective accounting policy permitted by SFAS 123.
Under this standard, since the exercise price of our stock options granted is
set equal to the market price on the date of the grant, we did not record any
expense to the condensed consolidated statement of income related to stock
options, unless certain original grant date terms were subsequently modified.
However, as required, we disclosed, in the Notes to Consolidated Financial
Statements, the pro forma expense impact of the stock option grants as if we
had applied the fair-value-based recognition provisions of SFAS 123.
The adoption of SFAS 123R primarily impacted our accounting
for stock options (See Note 13, Share-Based Payments).
Note 4. Asset Impairment Charge
In the first quarter of 2005, we recorded charges totaling
$1.2 billion ($766 million, net of tax) in connection with the
decision to suspend sales and marketing of Bextra. The pre-tax charge included
$1.1 billion related to the impairment of developed technology rights and
$10 million related to the write-off of machinery and equipment, both of which
were included in Other (income)/deductions - net (See Note 11, Goodwill
and Other Intangible Assets).
Note 5. Adapting to Scale Initiative
We incurred the following costs
in connection with our Adapting to Scale (AtS) productivity initiative, which
was launched in early 2005:
First
Quarter
(millions
of dollars)
2006
2005
Implementation
costs(a)
186
--
Restructuring
charges(b)
301
--
Total AtS costs
487
--
(a)
Included in Cost of sales
($124 million), Selling, informational and administrative expenses
($40 million), and Research and development expenses ($22 million).
(b)
Included
in Restructuring charges and merger-related costs.
Through April 2, 2006, the restructuring charges
primarily relate to our plant network optimization efforts and the
restructuring of our U.S. marketing and worldwide research and development operations,
while the implementation costs primarily relate to system and process
standardization, as well as the expansion of shared services.
The components of restructuring
charges associated with AtS follow:
(millions
of dollars)
Costs
Incurred
Through
April 2,
2006
Utilization
Through
April 2,
2006
Accrual
as of
April 2,
2006
(a)
Employee
termination costs
478
351
127
Asset
impairments
250
250
--
Other
23
16
751
608
143
(a)
Included
in Other current liabilities.
During the first quarter of 2006, we expensed $173 million
for Employee termination costs, $119 million for Asset
impairments and $9 million in Other. Through April 2, 2006,
Employee termination costs represent the approved reduction of
the workforce by 3,886 employees, mainly in manufacturing, sales and
research. We notified affected individuals and 3,610 employees were terminated
as of April 2, 2006. Employee termination costs are recorded as
incurred and include accrued severance benefits, pension and postretirement
benefits. Asset impairments primarily include charges to write-off inventory
and write down property, plant and equipment. Other primarily includes
costs to exit certain activities.
Note 6. Merger-Related Costs
We incurred the following
merger-related costs:
First
Quarter
(millions
of dollars)
2006
2005
Integration costs
106
Restructuring charges
113
Total
merger-related costs(a)
219
(a)
Included
in Restructuring charges and merger-related costs. Amounts in 2005
primarily relate to our acquisition of Pharmacia Corporation (Pharmacia),
which was completed on April 16, 2003.
Restructuring charges included severance, costs of vacating
duplicative facilities, contract termination and other exit costs.
Note 7. Taxes on Income
A. Taxes on Income
On January 23, 2006, the Internal Revenue Service (IRS)
issued final regulations on Statutory Mergers and Consolidations, which
impacted certain prior-period transactions. In the first quarter of 2006, we
recorded a tax benefit of $217 million, reflecting the total impact of these
regulations.
In the first quarter of 2005, we recorded an income tax
charge of $2.2 billion, included in Provision for taxes on income,
in connection with our decision to repatriate about $28.3 billion of
foreign earnings in accordance with the American Jobs Creation Act of 2004 (the
Jobs Act). This first quarter impact was based on preliminary information
available at the time. The final charge in 2005 was $1.7 billion on a
repatriation amount of $37 billion. The change in the repatriation and
corresponding tax amount was due primarily to guidance issued by the U.S.
Treasury in the second quarter of 2005, as well as our decision to increase the
amount of the repatriation.
B. Tax Contingencies
On January 25, 2006, the Company was notified by the IRS
Appeals Division that a resolution had been reached on the matter that we were
in the process of appealing related to the tax deductibility of a breakup fee
paid by Warner-Lambert Company in 2000. As a result, in the first quarter of
2006 we recorded a tax benefit of approximately $441 million related to
the resolution of this issue.
The IRS is currently conducting audits of the Pfizer Inc.
tax returns for the years 2002, 2003 and 2004. The 2005 and 2006 tax years are
also currently under audit under the IRS Compliance Assurance Process, a
recently introduced real time audit process.
With respect to Pharmacia Corporation, the IRS has completed
audits of the tax returns for the years 2000 through 2002 and is currently
conducting an audit for the 2003 tax year through the date of the merger with
Pfizer (April 16, 2003).
We periodically reassess the likelihood of assessments
resulting from audits of federal, state and foreign income tax filings. We
believe that our accruals for tax liabilities are adequate for all open years.
Note 8. Comprehensive Income/(Expense)
The components of comprehensive
income/(expense) follow:
First
Quarter
(millions
of dollars)
2006
2005
Net income
4,111
301
Other comprehensive
income/(expense):
Currency
translation adjustment and other
310
(277)
Net unrealized
gains/(losses) on derivative financial instruments
71
(19)
Net unrealized
gains/(losses) on available-for-sale securities
(71)
Minimum pension
liability
(12)
(2)
Total other
comprehensive income/(expense)
372
(369)
Total comprehensive
income/(expense)
4,483
(68)
Note 9. Financial Instruments
A. Long-Term Debt
On February
22, 2006, we issued the following Japanese yen fixed-rate bonds, to be used for
general corporate purposes:
$508 million
equivalent, senior unsecured notes, due February 2011, which pay interest
semi-annually, beginning on August 22, 2006, at a rate of 1.2%; and
$466 million
equivalent, senior unsecured notes, due February 2016, which pay interest
semi-annually, beginning on August 22, 2006, at a rate of 1.8%.
The notes were issued under a $5 billion
debt shelf registration filed with the SEC in November 2002. As of April 2,
2006, we had the ability to borrow $1 billion by issuing debt securities
under our existing debt shelf registration statement filed with the SEC in
November 2002.
B. Derivative
Financial Instruments and Hedging Activities
During the first quarter of
2006, we entered into the following incremental hedging activities:
Instrument(a)
Primary